Katherine Vandris

477 total citations
13 papers, 307 citations indexed

About

Katherine Vandris is a scholar working on Genetics, Molecular Biology and Rheumatology. According to data from OpenAlex, Katherine Vandris has authored 13 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 7 papers in Molecular Biology and 5 papers in Rheumatology. Recurrent topics in Katherine Vandris's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Kruppel-like factors research (5 papers) and Eosinophilic Disorders and Syndromes (4 papers). Katherine Vandris is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Kruppel-like factors research (5 papers) and Eosinophilic Disorders and Syndromes (4 papers). Katherine Vandris collaborates with scholars based in United States and United Kingdom. Katherine Vandris's co-authors include Richard T. Silver, Joshua J. Goldman, Paul J. Christos, Nicholas C.P. Cross, Y. Lynn Wang, Amy V. Jones, Robert L. Goodman, K. Chao, Bruce Turner and A. Gabriella Wernicke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Breast Cancer Research and Treatment.

In The Last Decade

Katherine Vandris

13 papers receiving 302 citations

Peers

Countries citing papers authored by Katherine Vandris

Since Specialization

Citations

This map shows the geographic impact of Katherine Vandris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Vandris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Vandris more than expected).

Fields of papers citing papers by Katherine Vandris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Vandris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Vandris. The network helps show where Katherine Vandris may publish in the future.

Co-authorship network of co-authors of Katherine Vandris

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Vandris. A scholar is included among the top collaborators of Katherine Vandris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Vandris. Katherine Vandris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. 2013 ·Journal of Clinical Oncology ·Deirdre Jill Cohen, Paul J. Christos, Joseph A. Sparano, Hedy L. Kindler, Daniel Virgil Thomas Catenacci, Tanios Bekaii‐Saab, Sanaa Tahiri, Yelena Y. Janjigian, Michael K. Gibson, Emily Chan, Lakshmi Rajdev, Susan G. Urba, James L. Wade, Peter Kozuch, (unknown), Katherine Vandris, Naoko Takebe, Howard S. Höchster	16
2	Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. 2013 ·Journal of Clinical Oncology ·Deirdre Jill Cohen, Paul J. Christos, Hedy L. Kindler, Daniel Virgil Thomas Catenacci, Tanios Bekaii‐Saab, Sanaa Tahiri, Yelena Y. Janjigian, Michael K. Gibson, Emily Chan, Lakshmi Rajdev, Susan G. Urba, James L. Wade, Peter Kozuch, (unknown), Katherine Vandris, Naoko Takebe, Howard S. Höchster, Joseph A. Sparano	33
3	Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera 2011 ·Haematologica ·Emil Kuriakose, Katherine Vandris, Y. Lynn Wang, (unknown), Amy V. Jones, Paul J. Christos, Nicholas C.P. Cross, Richard T. Silver	24
4	Treatment of polycythemia vera with imatinib mesylate 2011 ·Leukemia Research ·Richard T. Silver, (unknown), Katherine Vandris, Steven Fruchtman, Jerry L. Spivak, Eric J. Feldman, August J. Salvado	8
5	Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera, 2011 ·Blood ·Richard T. Silver, (unknown), Katherine Vandris, (unknown), (unknown), (unknown), Attilio Orazi, Stanley J. Goldsmith	4
6	Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report 2011 ·Blood ·Richard T. Silver, Katherine Vandris, Joshua J. Goldman	101
7	JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy 2010 ·Leukemia Research ·Richard T. Silver, Katherine Vandris, Y. Lynn Wang, (unknown), Amy V. Jones, Paul J. Christos, Nicholas C.P. Cross	51
8	A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance 2010 ·Breast Cancer Research and Treatment ·A. Gabriella Wernicke, Robert L. Goodman, Bruce Turner, Lydia Komarnicky, Walter J. Curran, Paul J. Christos, (unknown), Katherine Vandris, B. Parashar, Dattatreyudu Nori, K. Chao	59
9	Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV). 2009 ·Blood ·Richard T. Silver, Katherine Vandris, Joshua J. Goldman, (unknown), Y. Lynn Wang, Amy V. Jones, Paul J. Christos, Nicholas C.P. Cross	1
10	Normal Serum-Erythropoietin (S-epo) Level at Diagnosis of Polycythemia Vera (PV) Correlates with LowJAK2V617F Mutant Allele Burden and Indicates Mild Phenotype. 2009 ·Blood ·Joshua J. Goldman, Katherine Vandris, (unknown), (unknown), Richard T. Silver	2
11	Recombinant Interferon Alpha (rIFNα) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology. 2008 ·Blood ·Benjamin Levy, Katherine Vandris, (unknown), Joshua J. Goldman, Richard T. Silver	3
12	JAK2 Mutations Are Present in All Cases of Polycythemia Vera. 2007 ·Blood ·Y. Lynn Wang, Katherine Vandris, Amy V. Jones, Nicholas C.P. Cross, Paul J. Christos, (unknown), Richard T. Silver	2
13	JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity. 2007 ·Blood ·Richard T. Silver, Katherine Vandris, Y. Lynn Wang, Paul J. Christos, (unknown), Amy V. Jones, Nicholas C.P. Cross	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact